Research discovered no new safety signals.
Citing results published by the British Journal of Dermatology in a head-to-head study, AbbVie’s Skyrizi was deemed more effective when compared to Amgen’s Otezla among adult patients with moderate plaque psoriasis eligible for systemic therapy. The organization reported that the study achieved all primary and ranked secondary endpoints with no new safety signals identified.
As a collaboration with Boehringer Ingelheim, AbbVie leads development and global commercialization of Skyrizi.
"This study highlights the efficacy of SKYRIZI compared to Otezla in helping systemic-eligible patients achieve high levels of skin clearance and reinforces the safety profile observed in previous studies," said Mudra Kapoor, MD, VP, global medical affairs, immunology, AbbVie, in a company press release. "These head-to-head data are crucial to help patients and their doctors make informed treatment decisions for uncontrolled disease and add to the body of evidence supporting SKYRIZI as a treatment option for adults living with moderate psoriasis."
Reference: SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study. PR Newswire. July 26, 2023. Accessed July 27, 2023. https://www.prnewswire.com/news-releases/skyrizi-risankizumab-achieved-superiority-versus-apremilast-for-co-primary-endpoints-among-adult-patients-with-moderate-plaque-psoriasis-in-phase-4-head-to-head-study-301885778.html